1887

Journal of General Virology header logo

Volume 88, Issue 7

Activity of the LMP1 gene promoter in Epstein–Barr virus-transformed cell lines is modulated by sequence variations in the promoter-proximal CRE site Free

Abstract

The Epstein–Barr virus (EBV)-encoded tumour-associated latent membrane protein 1 (LMP1) gene expression is transactivated by EBV nuclear antigen 2 (EBNA2) in human B cells. We have previously identified a cyclic AMP-responsive element (CRE) in the B95-8 LMP1 promoter that is essential for transcription activation. Sequencing of LMP1 promoter in the P3HR1-derived EREB2.5 cell line revealed 25 single base pair substitutions in comparison to the B95-8 virus, one of them localized in the CRE element. Sequence variations in this element have been identified in several EBV isolates of both African and Asian origins. The effect of the P3HR1 CRE site variation on binding of factors to the LMP1 promoter sequence (LRS) and promoter activation was investigated with electrophoreticmobility-shift assays and reporter gene transfection assays. ATF1 and CREB1 transcription factors bound with reduced efficiency to the P3HR1 variant and below the detection level to the other tested variants. Accordingly, reporter plasmids carrying the P3HR1 CRE sequence in a B95-8 LRS context displayed 50 % lower activity in all tested cell lines. The impaired ability to activate transcription caused by the C to A substitution in CRE was not apparent when the mutated site was placed in a P3HR1 LRS context and the reporter transfected into Jijoye cells, most likely as a consequence of the other base pair substitutions in P3HR1 LRS. Overall, our results suggest that the mutations in the LRS CRE site have been conserved to adjust LMP1 expression to levels that favour cell survival in certain cellular and environmental contexts.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82771-0
2007-07-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/7/1887.html?itemId=/content/journal/jgv/10.1099/vir.0.82771-0&mimeType=html&fmt=ahah

References

  1. Baichwal V. R., Sugden B. 1988; Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461–467
     [Google Scholar]
  2. Ben-Bassat H., Goldblum N., Mitrani S., Goldblum T., Yoffey J. M., Cohen M. M., Bentwich Z., Ramot B., Klein E., Klein G. 1977; Establishment in continuous culture of a new type of lymphocyte from a “Burkitt like” malignant lymphoma (line D.G.-75). Int J Cancer 19:27–33 [CrossRef]
     [Google Scholar]
  3. Burrows J. M., Bromham L., Woolfit M., Piganeau G., Tellam J., Connolly G., Webb N., Poulsen L., Cooper L. other authors 2004; Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J Virol 78:7131–7137 [CrossRef]
     [Google Scholar]
  4. Chang M. H., Ng C. K., Lin Y. J., Liang C. L., Chung P. J., Chen M. I., Tyan Y. S., Hsu C. Y., Shu C. H., Chang Y. S. 1997; Identification of a promoter for the latent membrane protein 1 gene of Epstein-Barr virus that is specifically activated in human epithelial cells. DNA Cell Biol 16:829–837 [CrossRef]
     [Google Scholar]
  5. Chen M. L., Tsai C. N., Liang C. L., Shu C. H., Huang C. R., Sulitzeanu D., Liu S. T., Chang Y. S. 1992; Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131–2140
     [Google Scholar]
  6. Chen M. L., Wu R. C., Liu S. T., Chang Y. S. 1995; Characterization of 5′-upstream sequence of the latent membrane protein 1 (LMP-1) gene of an Epstein-Barr virus identified in nasopharyngeal carcinoma tissues. Virus Res 37:75–84 [CrossRef]
     [Google Scholar]
  7. Epstein M. A., Achong B. G., Barr Y. M., Zajac B., Henle G., Henle W. 1966; Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 37:547–559
     [Google Scholar]
  8. Fahraeus R., Jansson A., Ricksten A., Sjoblom A., Rymo L. 1990a; Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A 87:7390–7394 [CrossRef]
     [Google Scholar]
  9. Fahraeus R., Rymo L., Rhim J. S., Klein G. 1990b; Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345:447–449 [CrossRef]
     [Google Scholar]
  10. Fennewald S., van Santen V., Kieff E. 1984; Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51:411–419
     [Google Scholar]
  11. Floettmann J. E., Ward K., Rickinson A. B., Rowe M. 1996; Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223:29–40 [CrossRef]
     [Google Scholar]
  12. Gregory C. D., Murray R. J., Edwards C. F., Rickinson A. B. 1988; Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 167:1811–1824 [CrossRef]
     [Google Scholar]
  13. Gupta S., Campbell D., Derijard B., Davis R. J. 1995; Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389–393 [CrossRef]
     [Google Scholar]
  14. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R. Jr, Grace J. T., Jr. 1967; Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol 1:1045–1051
     [Google Scholar]
  15. Hu L. F., Chen F., Zheng X., Ernberg I., Cao S. L., Christensson B., Klein G., Winberg G. 1993; Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575–1583
     [Google Scholar]
  16. Hudson G. S., Farrell P. J., Barrell B. G. 1985; Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95–8. J Virol 53:528–535
     [Google Scholar]
  17. Jenkins P. J., Farrell P. J. 1996; Are particular Epstein-Barr virus strains linked to disease?. Semin Cancer Biol 7:209–215 [CrossRef]
     [Google Scholar]
  18. Kanai K., Satoh Y., Saiki Y., Ohtani H., Sairenji T. 2007; Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes 34:55–61 [CrossRef]
     [Google Scholar]
  19. Kaye K. M., Izumi K. M., Kieff E. 1993; Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90:9150–9154 [CrossRef]
     [Google Scholar]
  20. Kaye K. M., Izumi K. M., Mosialos G., Kieff E. 1995; The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675–683
     [Google Scholar]
  21. Kaykas A., Sugden B. 2000; The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation. Oncogene 19:1400–1410 [CrossRef]
     [Google Scholar]
  22. Kempkes B., Pawlita M., Zimber-Strobl U., Eissner G., Laux G., Bornkamm G. W. 1995; Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J κ in a conditional fashion. Virology 214:675–679 [CrossRef]
     [Google Scholar]
  23. Kieff E., Rickinson A. B. 2001; Epstein-Barr virus and its replication. In Fields Virology , 4th edn. pp 2511–2573 Edited by Knipe D. M., Howley P. M. Philadelphia, PA: Lippincott Williams & Wilkins;
     [Google Scholar]
  24. Kilger E., Kieser A., Baumann M., Hammerschmidt W. 1998; Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17:1700–1709 [CrossRef]
     [Google Scholar]
  25. Klein G., Dombos L., Gothoskar B. 1972; Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer 10:44–57 [CrossRef]
     [Google Scholar]
  26. Lam N., Sandberg M. L., Sugden B. 2004; High physiological levels of LMP1 result in phosphorylation of eIF2 α in Epstein-Barr virus-infected cells. J Virol 78:1657–1664 [CrossRef]
     [Google Scholar]
  27. Livingstone C., Patel G., Jones N. 1995; ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 14:1785–1797
     [Google Scholar]
  28. Masson N., John J., Lee K. A. 1993; In vitro phosphorylation studies of a conserved region of the transcription factor ATF1. Nucleic Acids Res 21:4166–4173 [CrossRef]
     [Google Scholar]
  29. Miller G., Shope T., Lisco H., Stitt D., Lipman M. 1972; Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A 69:383–387 [CrossRef]
     [Google Scholar]
  30. Mitchison N. A. 2001; Genetic variation in the MHC II promoter: lessons for regulation and for comparative genomics. Folia Biol (Praha) 47:183–186
     [Google Scholar]
  31. Moorthy R. K., Thorley-Lawson D. A. 1993; All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 67:1638–1646
     [Google Scholar]
  32. Narbonnet S., Mariame B. 2006; The Epstein-Barr virus oncoprotein LMP1 inhibits the activity of viral or cellular promoters without inducing cytostasis. Virology 350:381–393 [CrossRef]
     [Google Scholar]
  33. Pulvertaft J. V. 1965; A study of malignant tumours in Nigeria by short-term tissue culture. J Clin Pathol 18:261–273 [CrossRef]
     [Google Scholar]
  34. Ricksten A., Svensson C., Welinder C., Rymo L. 1987; Identification of sequences in Epstein-Barr virus DNA required for the expression of the second Epstein-Barr virus-determined nuclear antigen in COS-1 cells. J Gen Virol 68:2407–2418 [CrossRef]
     [Google Scholar]
  35. Sadler R. H., Raab-Traub N. 1995; The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat. J Virol 69:4577–4581
     [Google Scholar]
  36. Sandberg M. L., Kaykas A., Sugden B. 2000; Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression. J Virol 74:9755–9761 [CrossRef]
     [Google Scholar]
  37. Sandvej K., Andresen B. S., Zhou X. G., Gregersen N., Hamilton-Dutoit S. 2000; Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site. Mol Pathol 53:280–288 [CrossRef]
     [Google Scholar]
  38. Shaywitz A. J., Greenberg M. E. 1999; CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821–861 [CrossRef]
     [Google Scholar]
  39. Sheng M., Thompson M. A., Greenberg M. E. 1991; CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 252:1427–1430 [CrossRef]
     [Google Scholar]
  40. Sjoblom A., Yang W., Palmqvist L., Jansson A., Rymo L. 1998; An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol 72:1365–1376
     [Google Scholar]
  41. Takacs M., Salamon D., Myohanen S., Li H., Segesdi J., Ujvari D., Uhlig J., Niller H. H., Wolf H. other authors 2001; Epigenetics of latent Epstein-Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol Chem 382:699–705
     [Google Scholar]
  42. Tibbles L. A., Woodgett J. R. 1999; The stress-activated protein kinase pathways. Cell Mol Life Sci 55:1230–1254 [CrossRef]
     [Google Scholar]
  43. van Dam H., Wilhelm D., Herr I., Steffen A., Herrlich P., Angel P. 1995; ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 14:1798–1811
     [Google Scholar]
  44. Wang D., Liebowitz D., Kieff E. 1985; An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831–840 [CrossRef]
     [Google Scholar]
  45. Zetterberg H., Rymo L. 2005; EBNA2 transcription regulation in EBV latency. In Epstein Barr Virus pp 439–462 Edited by Robertson E. S. Norfolk, England: Caister Academic Press;
     [Google Scholar]
  46. Zhou X. G., Sandvej K., Li P. J., Ji X. L., Yan Q. H., Zhang X. P., Da J. P., Hamilton-Dutoit S. J. 2001; Epstein-Barr virus gene polymorphisms in Chinese Hodgkin's disease cases and healthy donors: identification of three distinct virus variants. J Gen Virol 82:1157–1167
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82771-0
Loading
Activity of the LMP1 gene promoter in Epstein–Barr virus-transformed cell lines is modulated by sequence variations in the promoter-proximal CRE site
J. Gen. Virol. 88, 1887 (2007); https://doi.org/10.1099/vir.0.82771-0
/content/journal/jgv/10.1099/vir.0.82771-0
/content/journal/jgv/10.1099/vir.0.82771-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error